Selected research
Industry Research
Cyclizine Industry Research Report 2026
Market perspective
The global Cyclizine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cyclizine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cyclizine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cyclizine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cyclizine include Teva, Glaxosmithkline, Wockhardt UK, Wabosan Arzneimittel, Pharmascript Limited, P and D Pharmaceuticals, Be-Tabs Pharmaceuticals, Aspen Pharmacare and Amoun Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cyclizine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cyclizine Market by Company
Teva
Glaxosmithkline
Wockhardt UK
Wabosan Arzneimittel
Pharmascript Limited
P and D Pharmaceuticals
Be-Tabs Pharmaceuticals
Aspen Pharmacare
Amoun Pharmaceutical
Amco
Aft Pharmaceuticals
Advanz Pharma
Cyclizine Segment by Type
Oral
Injection
Cyclizine Segment by Application
Migraine
Motion Sickness
Cyclizine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclizine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyclizine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclizine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cyclizine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cyclizine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cyclizine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Migraine
- Motion Sickness
Companies covered
- Teva
- Glaxosmithkline
- Wockhardt UK
- Wabosan Arzneimittel
- Pharmascript Limited
- P and D Pharmaceuticals
- Be-Tabs Pharmaceuticals
- Aspen Pharmacare
- Amoun Pharmaceutical
- Amco
- Aft Pharmaceuticals
- Advanz Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cyclizine Market Size (2021-2032)
- 2.2.2 Global Cyclizine Sales (2021-2032)
- 2.2.3 Global Cyclizine Market Average Price (2021-2032)
- 2.3 Cyclizine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injection
- 2.4 Cyclizine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Migraine
- 2.4.3 Motion Sickness
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cyclizine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cyclizine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Cyclizine Revenue of Manufacturers (2021-2026)
- 3.4 Global Cyclizine Average Price by Manufacturers (2021-2026)
- 3.5 Global Cyclizine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cyclizine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cyclizine, Product Type & Application
- 3.8 Global Manufacturers of Cyclizine, Established Date
- 3.9 Global Cyclizine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Cyclizine Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Glaxosmithkline
- 4.2.1 Glaxosmithkline Company Information
- 4.2.2 Glaxosmithkline Business Overview
- 4.2.3 Glaxosmithkline Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Glaxosmithkline Cyclizine Product Portfolio
- 4.2.5 Glaxosmithkline Recent Developments
- 4.3 Wockhardt UK
- 4.3.1 Wockhardt UK Company Information
- 4.3.2 Wockhardt UK Business Overview
- 4.3.3 Wockhardt UK Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Wockhardt UK Cyclizine Product Portfolio
- 4.3.5 Wockhardt UK Recent Developments
- 4.4 Wabosan Arzneimittel
- 4.4.1 Wabosan Arzneimittel Company Information
- 4.4.2 Wabosan Arzneimittel Business Overview
- 4.4.3 Wabosan Arzneimittel Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Wabosan Arzneimittel Cyclizine Product Portfolio
- 4.4.5 Wabosan Arzneimittel Recent Developments
- 4.5 Pharmascript Limited
- 4.5.1 Pharmascript Limited Company Information
- 4.5.2 Pharmascript Limited Business Overview
- 4.5.3 Pharmascript Limited Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pharmascript Limited Cyclizine Product Portfolio
- 4.5.5 Pharmascript Limited Recent Developments
- 4.6 P and D Pharmaceuticals
- 4.6.1 P and D Pharmaceuticals Company Information
- 4.6.2 P and D Pharmaceuticals Business Overview
- 4.6.3 P and D Pharmaceuticals Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 P and D Pharmaceuticals Cyclizine Product Portfolio
- 4.6.5 P and D Pharmaceuticals Recent Developments
- 4.7 Be-Tabs Pharmaceuticals
- 4.7.1 Be-Tabs Pharmaceuticals Company Information
- 4.7.2 Be-Tabs Pharmaceuticals Business Overview
- 4.7.3 Be-Tabs Pharmaceuticals Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Be-Tabs Pharmaceuticals Cyclizine Product Portfolio
- 4.7.5 Be-Tabs Pharmaceuticals Recent Developments
- 4.8 Aspen Pharmacare
- 4.8.1 Aspen Pharmacare Company Information
- 4.8.2 Aspen Pharmacare Business Overview
- 4.8.3 Aspen Pharmacare Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Aspen Pharmacare Cyclizine Product Portfolio
- 4.8.5 Aspen Pharmacare Recent Developments
- 4.9 Amoun Pharmaceutical
- 4.9.1 Amoun Pharmaceutical Company Information
- 4.9.2 Amoun Pharmaceutical Business Overview
- 4.9.3 Amoun Pharmaceutical Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Amoun Pharmaceutical Cyclizine Product Portfolio
- 4.9.5 Amoun Pharmaceutical Recent Developments
- 4.10 Amco
- 4.10.1 Amco Company Information
- 4.10.2 Amco Business Overview
- 4.10.3 Amco Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Amco Cyclizine Product Portfolio
- 4.10.5 Amco Recent Developments
- 4.11 Aft Pharmaceuticals
- 4.11.1 Aft Pharmaceuticals Company Information
- 4.11.2 Aft Pharmaceuticals Business Overview
- 4.11.3 Aft Pharmaceuticals Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Aft Pharmaceuticals Cyclizine Product Portfolio
- 4.11.5 Aft Pharmaceuticals Recent Developments
- 4.12 Advanz Pharma
- 4.12.1 Advanz Pharma Company Information
- 4.12.2 Advanz Pharma Business Overview
- 4.12.3 Advanz Pharma Cyclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Advanz Pharma Cyclizine Product Portfolio
- 4.12.5 Advanz Pharma Recent Developments
5 Global Cyclizine Market Scenario by Region
- 5.1 Global Cyclizine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cyclizine Sales by Region: 2021-2032
- 5.2.1 Global Cyclizine Sales by Region: 2021-2026
- 5.2.2 Global Cyclizine Sales by Region: 2027-2032
- 5.3 Global Cyclizine Revenue by Region: 2021-2032
- 5.3.1 Global Cyclizine Revenue by Region: 2021-2026
- 5.3.2 Global Cyclizine Revenue by Region: 2027-2032
- 5.4 North America Cyclizine Market Facts & Figures by Country
- 5.4.1 North America Cyclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cyclizine Sales by Country (2021-2032)
- 5.4.3 North America Cyclizine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Cyclizine Market Facts & Figures by Country
- 5.5.1 Europe Cyclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cyclizine Sales by Country (2021-2032)
- 5.5.3 Europe Cyclizine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Cyclizine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cyclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cyclizine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cyclizine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cyclizine Market Facts & Figures by Country
- 5.7.1 South America Cyclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cyclizine Sales by Country (2021-2032)
- 5.7.3 South America Cyclizine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Cyclizine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cyclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cyclizine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cyclizine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Cyclizine Sales by Type (2021-2032)
- 6.1.1 Global Cyclizine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Cyclizine Sales Market Share by Type (2021-2032)
- 6.2 Global Cyclizine Revenue by Type (2021-2032)
- 6.2.1 Global Cyclizine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cyclizine Revenue Market Share by Type (2021-2032)
- 6.3 Global Cyclizine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cyclizine Sales by Application (2021-2032)
- 7.1.1 Global Cyclizine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Cyclizine Sales Market Share by Application (2021-2032)
- 7.2 Global Cyclizine Revenue by Application (2021-2032)
- 7.2.1 Global Cyclizine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cyclizine Revenue Market Share by Application (2021-2032)
- 7.3 Global Cyclizine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cyclizine Value Chain Analysis
- 8.1.1 Cyclizine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cyclizine Production Mode & Process
- 8.2 Cyclizine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cyclizine Distributors
- 8.2.3 Cyclizine Customers
9 Global Cyclizine Analyzing Market Dynamics
- 9.1 Cyclizine Industry Trends
- 9.2 Cyclizine Industry Drivers
- 9.3 Cyclizine Industry Opportunities and Challenges
- 9.4 Cyclizine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst